February 7, 2025- McKesson Corporation announced that the McKesson board of directors has elected Lynne Doughtie and Dr. Julie Gerberding to join the board, effective February 3, 2025. Ms. Doughtie will serve on the Audit Committee and the Finance Committee, and Dr. Gerberding will serve on the Compliance Committee and the Compensation and Talent Committee. With these appointments, the McKesson board increases to 13 members, 12 of whom are independent.
Ms. Doughtie brings accounting and finance expertise as the former Chair and Chief Executive Officer of KPMG U.S. Ms. Doughtie spent over 30 years at KPMG, during which she gained depth of experience across various industries, including technology, healthcare, and financial services. She currently serves on the board of directors of The Boeing Company and Workday, Inc.
Dr. Gerberding brings extensive executive experience in the healthcare industry and public policy as the Chief Executive Officer of the Foundation for the National Institutes of Health. Previously, she served as the Executive Vice President and Chief Patient Officer at Merck & Co., and she also served as the Director of the Centers for Disease Control and Prevention. Dr. Gerberding currently serves on the board of directors of Hillevax, Inc., a biopharmaceutical company focused on the development and commercialization of novel vaccines.